Dossier
clinicaltrials
trial early
Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.
Key claim: A clinical study is evaluating ruxolitinib given before, during, and after allogeneic HSCT as treatment for primary or secondary myelofibrosis.
Abstract
This research study is studying a drug called Ruxolitinib as a possible treatment for Myelofibrosis.
Why this matters
A clinical study is evaluating ruxolitinib given before, during, and after allogeneic HSCT as treatment for primary or secondary myelofibrosis.